Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial.


Demir A., Molinas Mandel N., Paydaş S., Demir O. G. , Er Ö., Turhal N. S. , ...More

Balkan Medical Journal, vol.37, no.2, pp.104-107, 2020 (Journal Indexed in SCI Expanded)

  • Publication Type: Article / Article
  • Volume: 37 Issue: 2
  • Publication Date: 2020
  • Title of Journal : Balkan Medical Journal
  • Page Numbers: pp.104-107

Abstract

Background: The synthesis of CDK4/6 inhibitors with endocrine treatment in two series of treatment has been widely accepted as the standard for patients with estrogen receptor-positive metastatic breast cancer. In spite of this, the activity of CDK4/6 inhibitors in patients with metastatic breast cancer who have progressed despite receiving multiple lines of treatment is not well understood.

Aims: To report the activity and safety of a CDK4/6 inhibitor (palbociclib) in patients in whom at least three lines of treatment for ER+ metastatic breast cancer had failed.

Study Design: Multicenter retrospective observational cohort study.

Methods: In this retrospective observational cohort study, we included 43 patients who received palbociclib after at least three lines of systemic treatment for ER+/HER2− metastatic breast cancer.

Results: The median progression-free survival in our population was 7 months (25th-75th percentile, 4-10), and the median overall survival was 11 months (25th-75th percentile, 6-19). Although there were some adverse events, palbociclib was generally well tolerated, so dose reduction was needed for only six patients (14%).

Conclusion: The efficacy of palbociclib among heavily treated hormone receptor-positive/HER2− patients with advanced breast cancer was acceptable in terms of clinical benefit, and it was generally well tolerated among this population.

Keywords: Breast cancer, CDK4/6 inhibitors, palbociclib

Address for Correspondence: Atakan Demir, Department of Medical Oncology, Acıbadem University, İstanbul, Turkey

Phone: +